Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-

Modify Date: 2025-08-25 14:27:22

Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo- structure	Common Name	Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-
	CAS Number	23623-31-6	Molecular Weight	459.53200
	Density	1.23g/cm3	Boiling Point	N/A
	Molecular Formula	C₂₅H₃₃NO₇	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-

Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity[1][2].

Name	Lankacidin C
Synonym	More Synonyms

Description	Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
In Vivo	Lankacidin C (75-1000 mg/kg；腹腔注射；一天一次持续 5 天) 以剂量依赖性方式延长了 (C57BL/6×DBA/2) F1 (BDF1) 小鼠的平均生存时间。Lankacidin C (1000 mg/kg) 在植入 B-16 黑色素瘤的 C57BL/6 小鼠中显著抑制了 B-16 黑色素瘤的生长[2]。 Lankacidin C (300 mg/kg；腹腔注射；一天一次持续 6 天) 在含有L-1210/6-巯基嘌呤或 L-1210/阿糖胞苷的 BDF1 小鼠中，抑制对 6-巯基嘌呤 (6-Mercaptopurine，HY-13677) 或阿糖胞苷 (Cytosine Arabinoside，HY-13605) 耐药的 L-1210 细胞活性[2]。 Lankacidin C (10-100 mg/kg；腹腔注射；一天一次持续 5 天) 显著延长了含有 6C3 HED/OG 或 6C3 HED/RG 淋巴肉瘤的 C3H/He 小鼠平均生存时间[2]。 Lankacidin C (500 mg/kg；腹腔注射；一天一次持续 3 或 4 天) 在抗原刺激前后抑制 ICR 小鼠抗绵羊红细胞抗体的产生[2]。 Animal Model: C57BL/6, C3H/He, ICR and (C57BL/6×DBA/2) F1 (BDF1) mice[2]. Dosage: 10, 20, 25, 30, 40, 50, 100, 150, 250, 300, 500, 600 or 1000 mg/kg Administration: Intraperitoneal injection; once daily for 3, 4, 5 or 6 days Result: Inhibited the growth of L1210 leukemia, B16 melanoma and 6C3 HED/OG or 6C3 HED/RG lymphosarcoma cells.
References	[1]. Cai L, et al. Modular Approaches to Lankacidin Antibiotics. J Am Chem Soc. 2020 Sep 2;142(35):15116-15126. [2]. Ootsu K, et al. Effects of Lankacidin group (T2636) antibiotics on the tumor growth and immune response against sheep erythrocytes in mice. Gan. 1973 Oct;64(5):481-92.

Density	1.23g/cm3
Molecular Formula	C₂₅H₃₃NO₇
Molecular Weight	459.53200
Exact Mass	459.22600
PSA	130.00000
LogP	2.10860
Index of Refraction	1.566

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UZ0780000

CHEMICAL NAME :: Pyruvamide, N-(7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-1 6-oxabicyclo(13.2.2) nonadeca-3,5,9,11-tetraen-2-yl)-, (all-E)-(1S,2R,7S,13S,15R,19R)-(-)-

CAS REGISTRY NUMBER :: 23623-31-6

LAST UPDATED :: 199112

DATA ITEMS CITED :: 2

MOLECULAR FORMULA :: C25-H33-N-O7

MOLECULAR WEIGHT :: 459.59

WISWESSER LINE NOTATION :: T6-17- A B AOV DV IU KU OU QUTJ C1 E1 HQ K1 NQ Q1 SMVV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 85FZAT "Index of Antibiotics from Actinomycetes," Umezawa, H. et al., eds., Tokyo, Univ. of Tokyo Press, 1967 Volume(issue)/page/year: -,184,1967

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JANTAJ Journal of Antibiotics. (Japan Antibiotics Research Assoc., 2-20-8 Kamiosaki, Shinagawa-ku, Tokyo, 141, Japan) V.2-5, 1948-52; V.21- 1968- Volume(issue)/page/year: 26,647,1973

Glycine-d5

CAS#:4896-77-9

Propanamide,N-[...

CAS#:23623-31-6

Propanamide,N-[...

CAS#:23477-98-7

Literature: Kakinuma, Katsumi; Uzawa, Jun; Uramoto, Masakazu Tetrahedron Letters, 1982 , vol. 23, # 50 p. 5303 - 5306

Precursor 1
CAS#:4896-77-9 Glycine-d5
DownStream 0

Bundlin A

(-)-lankacidin C

Antibiotic T-2636C

N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-Dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxopropanamide

lankacidins

Lankacidin

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-

Use of Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-

Names

Biological Activity

Chemical & Physical Properties

Toxicological Information

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

Synthetic Route

Precursor & DownStream

Synonyms

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.